Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of MNC-QQ cell–enhanced autologous fat grafting for breast augmentation
jRCTb030230627Phase 2Suspended
- Start
- Feb 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Hypomastia. Primary endpoint: Safety of MNC-QQ-added fat grafting. Started Feb 2024; status: suspended.
02
Conditions
Hypomastia
Beyond the preview
Go deeper on jRCTb030230627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTb030230627.